Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amuvatinib + topotecan
- Development stage
- Unknown
- Lead developer
- Astex Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Amuvatinib (MP-470) is a multi-targeted tyrosine kinase inhibitor with potent activity against several validated cancer targets including mutant forms of c-Kit and platelet-derived growth factor receptor alpha. Its mechanism of action involves inhibition of DNA repair by downregulating RAD51 expression, which impairs homologous recombination and sensitizes tumor cells to DNA-damaging agents such as chemotherapy and radiation. Topotecan is a semi-synthetic derivative of camptothecin that acts as a topoisomerase I inhibitor; it interferes with the DNA replication process in cancer cells by stabilizing the cleavable complex between DNA and topoisomerase I, leading to cell death. The combination has been investigated for synergistic effects in treating cancers such as small cell lung cancer (SCLC), particularly in platinum-refractory cases[2][5][7].
- Brand names
- Hycamtin
- Other names
- MP470MP-470MP 470amuvatinib hydrochloridetopotecan hydrochloride
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)RAD51 (RAD51 Recombinase)TOP1 (DNA Topoisomerase I)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on amuvatinib + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amuvatinib + topotecan.